The efficacy and safety of daily rituximab in patients with systemic rheumatoid vasculitis has been examined based on data from 17 patients enrolled on the French AutoImmunity and Rituximab registry. After 6 months of treatment, 12 patients achieved complete remission of their vasculitis. However, maintenance therapy with rituximab might be necessary to prevent relapse: in 2 out of 3 patients who relapsed when rituximab was discontinued (from a total of 9 relapses), remission was re-established when the drug was reintroduced.
ORIGINAL RESEARCH PAPER
Puéchal, X. et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis. Results from the autoimmunity and rituximab registry. Arthritis Care Res. doi:10.1002/acr.20689
Rights and permissions
About this article
Cite this article
Achieving remission from systemic rheumatoid vasculitis. Nat Rev Rheumatol 8, 2 (2012). https://doi.org/10.1038/nrrheum.2011.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.195